The clearance of apoptotic cells is one of the most important processes of the immune system and is necessary for the homeostatic maintenance of healthy tissues and the removal of infected or damaged cells [1] [2] [3] . Several types of cells are able to take up apoptotic cells, including both professional scavengers (macrophages and dendritic cells (DCs)) and nonprofessional phagocytes (fibroblasts, endothelial and epithelial cells). In vivo, phagocytes are responsible for the rapid removal of dying cells before necrosis, a post-apoptotic stage accompanied by loss of membrane integrity and leakage of noxious intracellular molecules into the surrounding tissues 4, 5 . The phagocyte engulfment of apoptotic cells occurs by an immunologically silent process through the activation of immunosuppressive pathways and the production of anti-inflammatory cytokines to prevent an immune response to self antigens 6 . Consequently, defects in the recognition and/or engulfment of apoptotic cells can lead to chronic inflammatory diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, glomerulonephritis and atherosclerosis 7 . Several studies have shown that patients with the autoimmune disease SLE have more circulating apoptotic cells, indicative of a failure in the clearance of dying cells 8 . In addition, patients with lupus have circulating autoantibodies with specificity to intracellular autoantigens, which further emphasizes the importance of the clearance of apoptotic cells in maintaining tolerance and preventing autoimmunity.
During apoptosis, phosphatidylserine is externalized from the inner leaflet of the cell membrane to its outer leaflet, where it serves as a chief recognition and 'eat-me' signal for phagocytes 9 . Several cellsurface receptors (such as TIM-1, TIM-3, TIM-4 and BAI) and soluble bridging proteins (such as MFG-E8, calreticulin and the complement component C1q) can specifically bind to phosphatidylserine exposed on the surface of dying cells and enhance the uptake of apoptotic cells by phagocytes [10] [11] [12] [13] [14] [15] . The mechanism used by those bridging molecules awaits further characterization; however, studies have demonstrated that calreticulin acts as an 'eat-me' signal on the surface of apoptotic cells, whereas that signal is overridden on live cells by 'do-not-eatme' signals involving the signal-regulatory protein CD47 (IAP) 16 . Furthermore, the proposal of an important role for C1q and MFG-E8 in clearance of apoptotic cells is supported by data demonstrating the accumulation of apoptotic cells and the development of lupusassociated autoimmune disease in mice deficient in C1q or MFG-E8 (refs. 17-19) . Other studies have demonstrated that C1q, calreticulin and phosphatidylserine have strong interactions with each other and have suggested a combinatorial role for these three molecules in the recognition of apoptotic cells 14 . So far, the identification of the full range of receptors used by phagocytes to recognize and engulf apoptotic cells opsonized by C1q, calreticulin and/or MFG-E8 in vivo has remained elusive.
Scavenger receptors are a large family of structurally diverse molecules that have been linked to the recognition of endogenous host-derived ligands and microbial pathogens 20 . SCARF1 (originally called 'scavenger receptor expressed by endothelial cell 1' (SREC-1) after it was cloned from a cDNA library of endothelial cells) is an 86-kilodalton single-pass type 1 transmembrane protein composed of 830 amino acids 21 . The extracellular domain is made up of 406 amino acids and contains five epidermal growth factor (EGF)-like cysteinerich repeats, followed by a long carboxy-terminal cytoplasmic tail (391 amino acids) composed of serine-and proline-rich regions.
RESULTS

SCARF1 mediates the recognition of dying cells
The C. elegans receptor CED-1 and its mammalian ortholog SCARF1 function in innate sensing of the fungal pathogen Cryptococcus neoformans 27, 30 . To identify other ligands of SCARF1, we constructed a chimera composed of the extracellular domain of SCARF1 fused to the intracellular domain of the TNFRSF1A (TNF-R1) receptor for tumor-necrosis factor (TNF) and expressed the resultant SCARF1-TNF-R1 fusion in HEK293T human embryonic kidney cells (Supplementary Fig. 1a ). The binding of ligand to the chimeric receptor triggered signaling via the adaptors TRAF2 and RIP1, which led to activation of the transcription factor NF-κB and expression of the gene encoding interleukin 8 (IL-8) in these reporter cells. For example, the addition of heat-killed C. neoformans to the reporter cells induced signaling by CED-1-TNF-R1 and mouse SCARF1-TNF-R1 and by a fusion of the fungal β-glucan receptor dectin-1 and TNF-R1 (Supplementary Fig. 1b) .
To determine whether SCARF1, like CED-1, is involved in the innate recognition of apoptotic cells, we exposed mouse embryonic fibroblasts (MEFs) to ultraviolet irradiation and added the resultant apoptotic 'UV-MEFs' to the reporter cells. We observed activation of reporter cell lines expressing mouse SCARF1-TNF-R1, human SCARF1-TNF-R1 or CED-1-TNF-R1 but not those expressing dectin-1-TNF-R1 (Fig. 1a) . Furthermore, the activation of cells expressing SCARF1-TNF-R1 correlated with the number of apoptotic cells placed in coculture, but the activation of cells expressing dectin-1-TNF-R1 did not, and the former activation was blocked by the addition of recombinant soluble extracellular human SCARF1 (Fig. 1b,c) . As an additional control, we generated reporter cells expressing human SCARF2, a related member of the scavenger receptor family with 35% amino acid homology to SCARF1 (ref. 31) . In contrast to the results obtained for SCARF1, apoptotic cells did not trigger signaling by SCARF2-TNF-R1 reporter cells (Fig. 1b) , which indicated the specificity of SCARF1 in the sensing of apoptotic cells. By a conventional flow cytometry assay, we found that cells expressing SCARF1-TNF-R1 captured dye-labeled UV-MEFs, but those expressing dectin-1-TNF-R1 did not (Fig. 1c) , which indicated a direct interaction between SCARF1 and apoptotic cells. Microscopic analysis of cells expressing SCARF1-TNF-R1 showed binding to apoptotic cells, npg but only cells expressing full-length SCARF1 engulfed apoptotic cells by phagocytosis (data not shown), which indicated that the carboxyterminal cytoplasmic tail of SCARF1 was needed to signal the actin cytoskeleton for internalization. As live cells did not trigger SCARF1 signaling (Fig. 1a) , we sought to determine at what apoptotic stage ligands for SCARF1 were exposed on dying cells. We found that both early apoptotic cells (1-3 h after ultraviolet irradiation) and late apoptotic cells (8-24 h after ultraviolet irradiation) that had undergone secondary necrosis, as assessed by permeability to the DNA stain propidium iodide, triggered SCARF1-TNF-R1 signaling (Fig. 1d) , which indicated that ligands for SCARF1 were exposed soon after cell death. We also found that SCARF1 signaling was independent of the method used to induce cell death. We induced death in MEFs by osmotic shock or exposure to 137 Cs (γ-irradiation) and found that the addition of those dying to the reporter cells induced SCARF1-TNF-R1 signaling similar to the addition of UV-MEFs (Fig. 1e) . Moreover, all apoptotic cell types tested (B cells, DCs, splenocytes and MEFs), regardless of the species of origin, induced SCARF1-TNF-R1 signaling (Fig. 1e and data not shown), which indicated that the ligand was not restricted to the cell type or species. MFG-E8 has been shown to bind to apoptotic cells and facilitate their clearance through interaction with phagocytes 18 . We found that treatment of the reporter cells with recombinant MFG-E8 alone or in combination with apoptotic cells did not trigger or enhance SCARF1-TNF-R1 signaling (Supplementary Fig. 1c) , which indicated that MFG-E8 was not a ligand for SCARF1. Together these data demonstrated that the CED-1-like scavenger receptor SCARF1 shared an evolutionarily conserved function with CED-1 in the recognition of apoptotic cells.
SCARF1 binds to C1q
The exposure of phosphatidylserine on the outer leaflet of the plasma membrane of apoptotic cells is considered to be the main 'eat-me' signal recognized by phagocytes 9 . As signaling via SCARF1 and binding of SCARF1 to apoptotic cells coincided with their rapid exposure of phosphatidylserine, we hypothesized that phosphatidylserine is a ligand of SCARF1. To examine direct interactions between SCARF1 and phosphatidylserine, we used a protein-lipid overlay dot-blot assay in which we spotted hydrophobic membranes with 15 different lipids present in cell membranes and then probed the membranes with SCARF1 protein. In contrast to MFG-E8, SCARF1 did not bind to phosphatidylserine or any other lipids, except 3-sulfogalactosylceramide, a known ligand of scavenger receptors 32 ( Fig. 2a and Supplementary Fig. 2a ). To determine whether the recognition of apoptotic cells by SCARF1 was mediated by 3-sulfogalactosylceramide, we added UV-MEFs to reporter cells expressing SCARF1-TNF-R1, in the presence of 3-sulfogalactosylceramide. We observed that 3-sulfogalactosylceramide did not enhance or inhibit the activation of SCARF1 by apoptotic cells (Supplementary Fig. 2b ), which indicated that 3-sulfogalactosylceramide (sulfatide) was not an important contributor to the SCARF1-apoptotic cell interactions. 
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In addition to phosphatidylserine, several soluble bridging proteins have been shown to be involved in the recognition of apoptotic cells, including C1q, calreticulin and MFG-E8 (refs. 12,16,19) . Through the use of a protein-protein overlay dot-blot assay, we found that SCARF1 specifically bound to C1q in a concentration-dependent manner, but did not bind to calreticulin or MFG-E8 (Fig. 2b) . We further examined the direct binding of SCARF1 to C1q by antigencapture enzyme-linked immunosorbent assay (ELISA) with C1q-coated microtiter plate wells. These experiments showed strong binding of SCARF1 to C1q and to the classic scavenger receptor ligand acLDL, but negligible binding of SCARF1 to bovine serum albumin (BSA), phosphatidylserine, phosphatidylcholine or calreticulin (Fig. 2c) . Moreover, we observed a similar interaction pattern by ELISA in the reverse configuration, with C1q binding to platebound SCARF1 (data not shown). To confirm those findings and determine the affinity of the SCARF1-C1q interaction, we assessed the binding of SCARF1 to a C1q-immobilized sensor chip by measuring surface plasmon resonance. We observed no binding of SCARF1 to phosphatidylserine or calreticulin; however, we noted an affinity dissociation constant of 1.24 × 10 −7 M for the interaction of SCARF1 and C1q. These results identified C1q as a ligand for SCARF1.
SCARF1 recognizes dying cells via C1q-phosphatidylserine
To further investigate the interaction of SCARF1 with ligands on apoptotic cells, we cultured reporter cells expressing SCARF1-TNF-R1 with apoptotic cells deficient in C1q, MFG-E8 or calreticulin. Apoptotic cells deficient in C1q were significantly impaired in their ability to induce SCARF1 signaling, but those deficient in MFG-E8 or calreticulin were not ( Fig. 2d and Supplementary Fig. 2c ). In addition, C1q alone or in the presence of apoptotic cells triggered SCARF1 signaling (Il8 expression) in a concentration-dependent manner (Fig. 2e) . In contrast, treatment with calreticulin was not sufficient to enhance or inhibit the SCARF1-mediated recognition of apoptotic cells (Fig. 2e) . Together these data demonstrated that the recognition of apoptotic cells by SCARF1 required C1q.
As C1q has been shown to interact with phosphatidylserine on apoptotic cells, we hypothesized that the recognition of apoptotic cells by SCARF1 occurred via a C1q-phosphatidylserine-apoptotic cell interaction 13 . To test our hypothesis, we cultured reporter cells with apoptotic MEFs pretreated with annexin V, a phospholipidbinding protein with high affinity for phosphatidylserine, which binds to exposed phosphatidylserine on apoptotic cells. Pretreatment of apoptotic MEFs with annexin V, which blocked phosphatidylserine, inhibited the signaling of reporter cells expressing SCARF1-TNF-R1 and did so in a dose-dependent manner (Fig. 2f) . Moreover, to further determine whether the recognition of apoptotic cells by SCARF1 required phosphatidylserine, we did a liposome competition experiment. Liposomes containing phosphatidylserine inhibited apoptotic MEF-induced SCARF1-TNF-R1 signaling in a dose-dependent manner, but liposomes containing phosphatidylcholine did not; however, treatment with phosphatidylserine alone did not activate SCARF1 signaling (Fig. 2g) . Finally, to determine whether the SCARF1-C1q-apoptotic cell interaction was dependent on phosphatidylserine, we cultured reporter cells expressing SCARF1-TNF-R1 together with annexin V-treated apoptotic MEFs in the presence of C1q. We found that annexin V-treated apoptotic 
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MEFs did not activate SCARF1-dependent signaling, even in the presence of C1q (Fig. 2h) . Together these results demonstrated that the SCARF1-mediated recognition of apoptotic cells occurred by the binding of SCARF1 to C1q via phosphatidylserine exposed on apoptotic cells.
SCARF1 mediates the recognition of apoptotic cells in vitro
To determine where SCARF1 might serve its function, we did quantitative real-time PCR analysis to examine its expression in various organs of mice ( Supplementary Fig. 3a ). SCARF1 was expressed in a variety of organs, mainly in the spleen and lungs. Expression of SCARF1 was very low in circulating cells of the immune system (neutrophils, T cells and B cells; Fig. 3a) , consistent with published reports demonstrating its restricted expression on endothelial cells, DCs and macrophages 21, 22, 26, 30 . We also observed SCARF1 expression in peritoneal B-1a and B-1b cells equivalent to that in CD8α + DCs (Fig. 3a) . The addition of apoptotic cells to the cell culture medium resulted in higher expression of Scarf1 mRNA and higher surface expression of SCARF1 protein by CD8α + DCs, but not by other cell types (Fig. 3b,c) . The CD8α + DC subset is specialized in capturing dying cells 33 , so to further examine the role of SCARF1 in mediating the recognition of and responses to apoptotic cells, we generated SCARF1-deficient (Scarf1 −/− ) mice in which SCARF1 expression was ablated by replacement of exons 1-8, which encode the entire extracellular and transmembrane domains, with a neomycinresistance cassette ( Supplementary Fig. 4a-c) . To determine whether SCARF1 expression on CD8α + DCs was necessary for the capture and engulfment of apoptotic cells, we used flow cytometry to assess the frequency of the capture of dye-labeled apoptotic cells by CD8α + DCs isolated from Scarf1 +/+ and Scarf1 −/− mice. CD8α + DCs from Scarf1 −/− mice were significantly less able to acquire dye-labeled apoptotic cells than were Scarf1 +/+ CD8α + DCs (Fig. 3d) . These data demonstrated that SCARF1 was required for the recognition of apoptotic cells by CD8α + DCs. In addition to CD8α + DCs, Scarf1 −/− macrophages, endothelial cells and B-1a cells, but not neutrophils, B cells, T cells or B-1b cells, had significant impairment in their uptake of apoptotic cells, consistent with the expression of SCARF1 on these cell types (Fig. 3d) . These data showed that SCARF1 expression contributed approximately 70%, 32%, 74% and 52% to the clearance of apoptotic cells by CD8α + DCs, macrophages, endothelial cells and B-1a cells, respectively. As SCARF1 expression provided only a moderate contribution to the uptake of apoptotic cells by macrophages, these results suggested that other pathways for the clearance of apoptotic cells have a more dominant role in this cell type. Indeed, expression of receptors known to be involved in the recognition of apoptotic cells (MFG-E8, TIM-4, CD91 (LRP1), c-Mer and ITAGV) was significantly higher in macrophages than in CD8α + DCs or endothelial cells (P < 0.001; Supplementary Fig. 3b ), which suggested that these pathways may have partially compensated for the lack of SCARF1. As a control and to determine whether SCARF1 is a ligand for itself, we cultured Scarf1 +/+ CD8α + DCs together with apoptotic cells isolated from Scarf1 +/+ and Scarf1 −/− mice. Scarf1 +/+ CD8α + DCs engulfed an equivalent percentage of Scarf1 +/+ and Scarf1 −/− apoptotic cells (data not shown), which indicated that one of the shared ligands of SCARF1 on apoptotic cells was not SCARF1 itself. To confirm the uptake of apoptotic cells, we used confocal microscopy of CD8α + DCs incubated with dye-labeled apoptotic B cells. Scarf1 +/+ CD8α + DCs engulfed apoptotic cells and cleared them from the culture medium, but their Scarf1 −/− counterparts did not (Fig. 3e) . To further confirm the impairment in the internalization of apoptotic cells by Scarf1 −/− CD8α + DCs, we incubated CD8α + DCs with apoptotic cells labeled with pHrodo, a pH-sensitive fluorescent dye that makes engulfed cells highly fluorescent. Scarf1 −/− CD8α + DCs showed a substantial inability to engulf pHrodo-labeled apoptotic cells (Fig. 3f) . In contrast, Scarf1 +/+ and Scarf1 −/− CD8α + DCs engulfed an equivalent, but small, percentage of pHrodo-labeled live cells. To further test our hypothesis that SCARF1 mediates the recognition of apoptotic cells via C1q, we incubated Scarf1 +/+ and Scarf1 −/− CD8α + DCs with dye-labeled apoptotic cells in the presence or absence of C1q. C1q significantly enhanced the uptake of apoptotic cells by Scarf1 +/+ CD8α + DCs but not by Scarf1 −/− CD8α + DCs (Fig. 3g) . Together these experiments indicated that SCARF1 was required for optimal capture of apoptotic cells and was able to specifically 'sense' exposed ligands on apoptotic cells versus live cells.
The recognition of apoptotic cells requires SCARF1
To confirm that the deficiency in the clearance of apoptotic cells by SCARF1-deficient cells was not due to a secondary defect unrelated to the ablation of SCARF1, we reconstituted Scarf1 −/− CD8α + DCs, macrophages and endothelial cells with mouse Scarf1 cDNA through nucleofection. Ectopic expression of Scarf1, which we confirmed by immunoblot analysis and microscopy, restored the ability of Scarf1 −/− CD8α + DCs, macrophages and endothelial cells to efficiently capture apoptotic cells (Fig. 4 and data not shown) . Moreover, Scarf1 +/+ CD8α + DCs transfected with mouse Scarf1 cDNA had >25% more uptake of apoptotic cells than did mock-transfected Scarf1 +/+ CD8α + DCs (Fig. 4a) , which indicated that upregulation and/or overexpression of Scarf1 may be a useful therapeutic strategy for the clearance of dead cells that occurs in some diseases 1 .
SCARF1 mediates the clearance of apoptotic cells in vivo
To determine whether SCARF1 is necessary for the engulfment of apoptotic cells in vivo, we gave Scarf1 +/+ and Scarf1 −/− mice intravenous injection of dye-labeled apoptotic B cells or 1 µM latex spheres labeled with fluorescein isothiocyanate (FITC), as described 33 . We treated B cells with ultraviolet irradiation to induce apoptosis, which we confirmed by positive staining for annexin V and negative staining for propidium iodide. At 1 h after injecting apoptotic cells or FITC-latex beads, we collected spleens and enriched them for DCs through the use of magnetic microbeads coated with antibody 
to CD11c (anti-CD11c). We then used flow cytometry with antiCD11c and anti-CD8α to identify DCs that had captured apoptotic cells or FITC-latex beads. CD8α + and CD8α -DCs from Scarf1 +/+ and Scarf1 −/− mice captured equivalent amounts of FITC-latex beads (Fig. 5a) . In contrast, apoptotic cells were engulfed selectively by the CD8α + DC subset (Fig. 5b) . Moreover, CD8α + DCs from Scarf1 −/− mice captured significantly fewer apoptotic cells than did those from Scarf1 +/+ mice (Fig. 5b) . These data demonstrated that SCARF1 was necessary on CD8α + DCs for their capture of dying cells and that SCARF1 may be involved in the homeostatic clearance of apoptotic cells in vivo.
To test that hypothesis, we isolated peripheral blood mononuclear cells from the whole blood of 20-week-old Scarf1 +/+ and Scarf1 −/− mice. We then stained cells with annexin V and propidium iodide and used flow cytometry to quantify circulating apoptotic and necrotic cells. We found significantly more early apoptotic cells (positive for annexin V and negative for propidium iodide) and secondary necrotic cells (positive for annexin V and propidium iodide)-over fourfold and tenfold more, respectively-in the circulation of Scarf1 −/− mice than in that of Scarf1 +/+ mice (Fig. 5c) , which indicated an important role for SCARF1 in maintaining the clearance of apoptotic cells in vivo.
In wild-type mice, the removal of apoptotic cells is usually a very efficient process, and few apoptotic cells are found even in tissues with a high rate of cell death. However, dying cells accumulated in the tissues of Scarf1 −/− mice ( Fig. 5d and data not shown) . Notably, spleens from Scarf1 −/− mice had significantly more apoptotic cells, as assessed by the TUNEL cell-death assay, than did spleens from Scarf1 +/+ mice, and although splenic CD11c + DCs in Scarf1 −/− mice were located near apoptotic cells, they had less uptake of those cells than did their Scarf1 +/+ counterparts (Fig. 5d) . To ensure that the accumulation of apoptotic cells in Scarf1 −/− mice was due solely to the impairment in clearance of apoptotic cells and was not due to more cell turnover, we monitored the rate of apoptosis of Scarf1 +/+ and Scarf1 −/− cells. The rate and frequency of apoptosis of Scarf1 −/− splenocytes, B cells and bone marrow cells was similar to that of Scarf1 +/+ cells ( Supplementary Fig. 5a-c) . Furthermore, the expression of other receptors known to be involved in the recognition of apoptotic cells (C1q, MFG-E8, TIM-1, TIM-3, TIM-4, CD91, MARCO, CD14, LOX-1, SR-A1, GAS6, ITGAV and c-Mer) was not affected in Scarf1 −/− DCs (Supplementary Fig. 5d ). From these results we concluded that SCARF1 was necessary for the ability of CD8α + DCs to engulf and clear apoptotic cells in vivo.
SCARF1 deficiency results in spontaneous autoimmunity
Defective clearance of apoptotic cells can enhance susceptibility to the autoimmune disease SLE, and autoantigens derived from those apoptotic cells can lead to the production of autoantibodies, a hallmark feature of lupus [34] [35] [36] . We hypothesized that the inability of Scarf1 −/− mice to clear apoptotic cells efficiently would result in spontaneous lupus-associated autoimmune disease. To test our hypothesis, we used an indirect fluorescent antibody assay of antinuclear antibody (ANA) in human epithelial (HEp-2) cells as a sensitive method for detecting antibodies to both RNA-and DNA-containing autoantigens (Fig. 6a) . Beginning at ~20 weeks of age, a majority (~62%) of the serum from Scarf1 −/− mice produced a homogenous (~63%) or speckled (~37%) pattern of staining of nuclear ANA (Fig. 6b) . There was a significantly higher prevalence of ANA + serum from female Scarf1 −/− mice (17 of 22; ~77%) than from male Scarf1 −/− mice (11 of 25; ~48%; Fig. 6c) . Indeed, there is a strong gender bias in human SLE and in various animal models of lupus in which females are more susceptible to disease 37, 38 . Sex hormones and other genetic effects conferred by the female background may be involved in the generation of higher concentrations of systemic autoantibodies than those in male SCARF1-deficient mice 11 . In contrast, none of the serum from their Scarf1 +/+ littermates (control mice) produced any type of staining (Fig. 6a) , which indicated an absence of nuclear autoantibodies. The homogenous staining pattern in the majority of ANA + serum from Scarf1 −/− mice indicated autoantibodies to nucleoproteins and DNA, which have been reported to correlate with the clinical diagnosis of SLE. Autoantibodies with speckled staining patterns are also present in SLE and other disorders, notably Sjogren's syndrome. However, the specificity of the autoantibodies that produce the speckled pattern is less well defined but is often indicative of the presence of autoantibodies to the RNA-containing antigen Smith (SmRNP) and/or to the nuclear protein La. To further define the autoantibody profile, we used ELISA to quantify the higher concentration of autoantibodies to DNA-containing antigens in Scarf1 −/− serum. ELISA of autoantibodies to nucleosomes, in which the detection antigen was a combination of histones and double-stranded DNA (dsDNA), showed significantly higher concentration of autoantibodies specific for DNA-histone in Scarf1 −/− mice than in Scarf1 +/+ mice (Fig. 6d) . Consistent with the data obtained for ANA, female Scarf1 −/− mice generated significantly higher concentrations of autoantibodies to nucleosomes than did their male counterparts (Fig. 6d) . To determine if autoantibodies specific to dsDNA were present, we did the highly specific Crithida luciliae immunofluorescence assay. Male (13%) and female (22%) Scarf1 −/− mice had lower (but readily detectable) concentrations of anti-dsDNA autoantibodies in their serum than did Scarf1 +/+ mice (Fig. 6e) . Together these data indicated that autoantibodies in Scarf1 −/− mice 'preferentially' bound to DNA-histone epitopes rather than to nonchromatin DNA, which suggested that chromatin was the physiologically relevant autoantigen. We also quantified autoantibodies to SmRNP and La. Unlike our detection of antibodies to DNA-containing antigens, we did not detect the presence of serum antibodies to SmRNP or La (Fig. 6f and data not shown) ; thus, the autoantigen responsible for the speckled ANA pattern noted in ~23% of Scarf1 −/− mice remains to be identified.
Spontaneous inflammation in Scarf1 −/− mice
Because we had observed a significant effect of SCARF1 deficiency on autoantibody production, we next determined whether the absence of this receptor had a significant effect on other clinical manifestations npg A r t i c l e s of lupus-like autoimmune disease. Scarf1 −/− mice also had a significantly greater incidence and severity of skin disease, which was not present in wild-type mice (Fig. 7a) . Beginning at ~20 weeks of age, most Scarf1 −/− mice developed skin inflammation on their back, head and face, which was often accompanied by hair loss and whisker loss. Female Scarf1 −/− mice were more susceptible to skin disease than were their male counterparts. Cryosections of skin lesions from 20-week-old Scarf1 −/− female mice showed cellular infiltration and the presence of apoptotic cells (Fig. 7b) . In addition, we observed more splenomegaly in Scarf1 −/− mice over 20 weeks of age than in their agematched wild-type littermates (Fig. 7c) . Cryosection of spleens from Scarf1 −/− mice demonstrated they had larger germinal centers than did those of Scarf1 +/+ mice (Fig. 7d) . Scarf1 −/− mice had significantly more CD4 + T cells and B cells in the spleen (Fig. 7e) . The greater weight of Scarf1 −/− spleens was accompanied by the accumulation of lymphocytes with an activated phenotype. Scarf1 −/− mice had significantly more activated CD44 + CD4 + T cells and CXCR5 + Blimp-1 -Bcl-6 + CD4 + follicular helper T cells than did their wild-type counterparts (Fig. 7f,g ). As a measure of global B cell activation, we quantified total immunoglobulin G (IgG) in the serum. Scarf1 −/− mice had significantly higher concentrations of total serum IgG than Scarf1 +/+ mice, and this result was independent of the sex of the mice (Fig. 7h) . Together these data demonstrated that the genetic absence of Scarf1 led to spontaneous autoimmune disease activity and global activation of cells of the immune system.
Nephritis in Scarf1 −/− mice One of the important end-organ pathologies in lupus is nephritis. In agreement with other evidence of enhanced disease activity, Scarf1 −/− mice developed kidney disease. We observed greater glomerular size, cellularity and deposition of protein in periodic acid Schiffstained kidney sections from Scarf1 −/− mice than in their Scarf1 +/+ counterparts (Fig. 8a) . One of the main clinical pathogenic outcomes of circulating autoantibodies in lupus is their deposition as immunocomplexes in the kidney, which leads to glomerulonephritis 39 . Examination of kidney cryosections showed considerable deposition of IgG immunocomplexes in the glomeruli of Scarf1 −/− mice (Fig. 8b) . Meanwhile, female Scarf1 −/− mice had a significantly higher incidence and severity of renal disease than did male Scarf1 −/− mice (Fig. 8c) .
Consistent with that kidney disease, we found, by 24-hour quantitative urine collection, that >90% of Scarf1 −/− mice had at least moderate proteinuria (Fig. 8d) . Moreover, most female Scarf1 −/− mice also had pyuria and hematuria (Fig. 8e,f) . As another measure of kidney function, we also found that Scarf1 −/− mice had a significantly higher concentration of blood urea nitrogen than did Scarf1 +/+ mice (Fig. 8g) , indicative of ongoing kidney disease in the mutant mice. There was no statistically significant difference between male and female Scarf1 −/− mice or between Scarf1 +/+ mice and Scarf1 −/− mice in survival for up to 1 year (data not shown), which suggested that other pathways were able to partially compensate for Scarf1 deficiency and thereby allow these mice to tolerate this chronic autoimmune disease.
DISCUSSION
The data presented here have filled several gaps in the understanding of the clearance of apoptotic cells and regulation of autoimmunity. Here we have presented experimental evidence that SCARF1 is a receptor that is critical for the recognition and capture of apoptotic cells via binding to C1q that is adhered to newly exposed phosphatidylserine on the surface of the apoptotic cells, a process that is necessary for the prevention of lupus-like disease. That conclusion was based on the following: SCARF1 recognized and engulfed apoptotic cells at early stages of apoptosis before the loss of membrane integrity, a process critical for maintaining immunotolerance; the binding of SCARF1 to apoptotic cells and its uptake of those cells required exposure of C1q and phosphatidylserine on dying cells; evidence obtained by dot blot analysis, ELISA and measurement of surface plasmon resonance showed that SCARF1 recognized C1q specifically and avidly (K d = 1.24 × 10 −7 M); SCARF1-deficient mice accumulated apoptotic and necrotic cells in their blood and tissues; and SCARF1-deficient mice spontaneously developed clinical manifestations of lupus disease, including the generation of autoantibodies to chromatin, activation of cells of the immune system, skin inflammation and kidney disease (exemplified by the deposition of immunocomplexes in glomeruli, along with proteinuria). Together these data demonstrated an important role for SCARF1 in the removal of apoptotic cells in vitro and that its absence in vivo resulted in the spontaneous development of autoimmune disease.
The pathways that mediate engulfment of dying cells are conserved across evolution. In the worm, two partially redundant pathways exist b a Scarf1 A r t i c l e s for the removal of 'corpses' , with ced-1, ced-6 and ced-7 functioning in one pathway, and ced-2, ced-5, ced-10 and ced-12 functioning in the other 40 . In Drosophila, dead cells are engulfed by macrophages that express Draper, a receptor that is structurally and functionally similar to CED-1 (refs. 41,42) . In mammals, five proteins (MEGF10, MEGF11, Jedi-1, SCARF1 and CD91) have been identified that share homology with CED-1 and Draper 29, 43 . The expression of MEGF10 or Jedi-1 by glial cells has been shown to confer the ability to bind and engulf apoptotic neurons in vitro 44, 45 . However, a transgene encoding MEGF10 failed to 'rescue' the engulfment defect in CED-1-deficient worms, the ligands on apoptotic cells recognized by MEGF10 and Jedi-1 are not known, and mice deficient in these receptors that could be used to confirm those findings have not yet to been generated. The interaction of CD91 with apoptotic cells has been shown to occur through binding to calreticulin adherent to the surface of the apoptotic cells by C1q and/or phosphatidylserine 46 . Loss of CD91 impairs the uptake of apoptotic cells in vitro, but its role in vivo has not been determined, as CD91-deficient mice die early during gestation. CED-1 and SCARF1 share an evolutionarily conserved function in the recognition of and host defense against pathogenic fungi 27 . Here we found that SCARF1 also shares with CED-1 an evolutionarily conserved function in the capture of apoptotic cells. Furthermore, SCARF1 is the first C1q receptor, to our knowledge, that has been shown to be necessary for removal of apoptotic cells in vivo. Moreover, the susceptibility to and severity of the spontaneous autoimmune disease of SCARF1-deficient mice is similar to that of C1q-deficient mice 47 .
Many receptors and soluble bridging molecules have been linked to the clearance of apoptotic cells, and mice deficient in C1q, MFG-E8, TIM4 or c-Mer develop spontaneous autoimmune disease depending on their genetic background 10, 18, [47] [48] [49] . CD91 and calreticulin have also been shown to be involved in the uptake of apoptotic cells in vitro; however, their role in vivo remains unclear, as mice deficient in calreticulin or CD91 die in utero, which suggests that these pathways be important during development. Our in vitro and in vivo data demonstrated that the SCARF1 pathway for clearance of apoptotic cells was not completely nonredundant but contributed ~40-70% to the capture of apoptotic cells, depending on the type of phagocytic cell. These data indicated that other pathways for the clearance of apoptotic cells, such as phosphatidylserine-MFG-E8-integrins α v β 3 and β 5 , phosphatidylserine-calreticulin-CD91, and/or phosphatidylserine-TIM-3-TIM-4 probably contributed to the other 30-60%. Indeed, published studies have indicated that macrophages deficient in MFG-E8, calreticulin or C1q have ~75%, ~60% or ~50% less capture of apoptotic cells, respectively 10, 16, 18, 46 . This growing body of evidence, including our findings described here, suggests that all of these receptors partially contribute to the clearance of apoptotic cells, which may represent a new collective paradigm with which to explain clearance of apoptotic cells in vivo that has not been recognized, to our knowledge, before our work here. This hypothesis has been tested by studies showing that double deficiency in TIM4 and MFG-E8 results in a more deleterious phenotype than does single deficiency in either 50 . Similarly, we hypothesize that double deficiency in SCARF1 and MFG-E8 or in SCARF1 and TIM4 would result in a more deleterious phenotype than would single deficiency in any of those alone. For full understanding of the relative contribution of each molecule to clearance of apoptotic cells, future studies will need to generate such doubly deficient mice.
Collectively, these data indicate that the immune system has developed a fail-safe mechanism involving several receptors and bridging proteins expressed by different cell types and in specific organs for the removal of dying cells to maintain tolerance and prevent autoimmunity. The identification of the main molecules and receptors and how they function to internalize and process apoptotic debris could lead to therapeutic exploitation not only for the removal of unwanted cells but as an immunosuppressive or anti-inflammatory strategy. As in human patients, the lupus phenotype of SCARF1-deficient mice was more prevalent and severe in females, which indicates that SCARF1-deficient mice may be useful as a new model of spontaneous lupus for the study of human lupus that can be used to provide better understanding of the mechanisms used for the clearance of apoptotic cells in healthy and diseased states to identify targets for new therapeutic strategies.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Reagents. Reagents were from Sigma-Aldrich unless stated otherwise. Complete medium consisted of RPMI-1640 medium (Invitrogen) or DMEM (Invitrogen) supplemented with 100 U/ml penicillin, 100 U/ml streptomycin, 2 mM l-glutamine and 10% FCS. The HEK293T cell line (HCL4517) was from Fisher Scientific, and MEFs (SCRC-1008) were from American Type Culture Collection. All cell lines were free of mycoplasma, as determined by a Mycoplasma Detection PCR Kit (Sigma-Aldrich). Human anti-SCARF1 was from R&D Systems (monoclonal mouse IgG2B; 373606) and mouse anti-SCARF1 was from Proteintech (rabbit polyclonal; 13702-1-AP). All other antibodies were from eBioscience, unless otherwise specified.
Mice. All mice were maintained under microisolation in specific pathogenfree conditions at the animal facility of Massachusetts General Hospital under a protocol approved by the Institutional Animal Care and Use Committee. Wild-type C57BL/6 mice were from The Jackson Laboratories. To generate Scarf1 −/− mice, we constructed a targeting vector that contained 4.42 kilobases of 5′ sequence upstream of the transcriptional start site, a neomycin-resistance cassette that replaced exons 1-8 (which encode the entire extracellular and transmembrane domains), and 1.85 kilobases of 3′ sequence spanning exons 9-10. The primers used to amplify the 5′ long arm and the 3′ short arm were as follows: 5′ long arm forward (5Arm Fw1), 5′-CCCAGTCCTCCTGGAAC TACAACTT-3′, and reverse (5Arm Rv1), 5′-CCACAGGTCCCTGAAACAC TAGAGA-3′; and 3′ short arm forward (3Arm Fw1), 5′-AAGAAAAGTGAA ATCAGAGCCGACA-3′, and reverse (3Arm Rv1), 5′-CCAAAACACCATTA CTACTGCCGAA-3′. Those genomic regions were ligated into the targeting vector OSDupDel.Neo (Open Biosystems). The linearized vector was transfected into C57BL/6 ES cells by electroporation by the inGenious Targeting Laboratory, and targeted clones that were selected in the presence of the antibiotic neomycin were identified by PCR and Southern blot analysis. Targeted embryonic stem cell clones were injected into C57BL/6 mice blastocysts, which yielded several lines of chimeric mice that transmitted the disrupted allele through germline DNA. Offspring of Scarf1 −/− mice were produced at normal Mendelian ratios. Mice were not randomized or placed in specific groups for these studies.
Genotyping and Southern blot analysis of Scarf1. Homologous recombination in electroporated embryonic stem cell clones or genomic DNA obtained from tail tissue was assessed by PCR and Southern blot analysis. PCR primer pairs were as follows: wild-type forward (WT Fw1), 5′-AGCCTGGAACTGCATGTC TT-3′, and reverse (WT Rv1), 5′-TGAATGCCTTACAGCACAGC-3′; and Scarf1 −/− forward (KO Fw1), 5′-CTTCTATCGCCTTCTTGACGAGT-3′, and reverse (KO Rv1), 5′-TAGATACCTCTCCTTCGCTCT-3′. The probe (326-base pair) and primer pairs for Southern blot analysis were South Fw1 (forward), 5′-CAAGATGTCACCACTCATGCCAAAA-3′, and South Rv1 (reverse), 5′-ACAGGAGCATCTGAACCCTCTCGTA-3′. For screening by Southern blot analysis, genomic DNA was digested with BamHI before separation by electrophoresis through a gel. The DNA was transferred to nitrocellulose and incubated with a radiolabeled probe. The digestion pattern was a wild-type band at 5,110 base pairs and a 'gene-targeted' band at 6,122 base pairs.
Generation of apoptotic cells. Mouse primary B cells were isolated by negative selection from the spleen with an EasySep Mouse B Cell enrichment kit according to the manufacturer's instructions (STEMCELL Technologies). Apoptotic cells were generated from primary B cells, HEK293T cells and MEFs according to the method described below. For all assays, unless specified otherwise, apoptotic cells were labeled with CFSE (carboxyfluorescein diacetate succinimidyl ester) or pHrodo (Invitrogen).
For the generation of apoptotic cells by osmotic shock, cells were first centrifuged at 800g for 5 min. Cells were then washed once with PBS and resuspended for 10 min in hypertonic media (DMEM supplemented with 10% (wt/vol) polyethylene glycol 1000, 0.5 M sucrose, 10 mM HEPES, pH 7.2). Immediately afterward, 30 ml of hypotonic medium (60% DMEM and 40% water) was added, followed by incubation for 5 min. Cells were then washed and resuspended in complete DMEM, followed by culture for 3 h at 37 °C. The generation of apoptotic cells by ultraviolet radiation was done by placement of a flask of cells into a ultraviolet transilluminator set to 100 Joules/m 2 , followed by culture for 3 h. The generation of apoptotic cells by 137 Cs irradiation was done by exposure of cells to 3,000 rads. Apoptotic cells were generated from Mfge8 −/− mice (a gift from Y.F. Peng) and from K41 (calreticulin-sufficient) and K42 (calreticulin-deficient) MEFs (a gift from M. Michalak). Cells were used when most cells were apoptotic, as defined by annexin V-positive and propidium iodide-negative staining by flow cytometry.
Generation of liposomes.
Small unilamellar vesicles (liposomes) were prepared as described 9 . Pure phospholipids were sonicated and specific phospholipids were prepared in sodium phosphate buffer by extrusion at 37 °C through a 0.1-µm polycarbonate filter with a mini-extruder set (Avanti polar lipids). Liposomes were composed of 100% mol phosphatidylcholine or a mixture of 70% mol phosphatidylcholine and 30% mol phosphatidylserine. Dot-blot and binding assays. Membrane lipid strips (Echelon Bioscience) were spotted with ten membrane lipids (100 pmol each). Nonspecific binding of membranes were blocked by incubation for 1 h with 3% BSA in TBS-T (50 mM Tris, 0.5 M NaCl and 0.05% Tween-20, pH 7.4). After that blockade, membranes were incubated for 1 h with soluble recombinant SCARF1 protein (R&D Systems), then were washed and incubated with anti-SCARF1 (mouse; 373606; R&D Systems), followed by incubation for 1 h with a horseradish peroxidase-labeled secondary antibody (goat; HAF007; R&D Systems). Binding was detected by chemiluminescent detection. ELISA was used to confirm the interaction of SCARF1 with other markers of apoptotic cells. PVC microtiter plates were coated overnight at 4 °C with acLDL, C1q, BSA, phosphatidylserine, phosphatidylcholine or calreticulin. Plates were washed and nonspecific binding was blocked, followed by incubation with SCARF1 protein and then primary antibodies (mouse; 373606; R&D Systems) and horseradish peroxidase-conjugated secondary antibodies (goat; HAF007; R&D Systems). Absorbance at 450 nm was measured with a plate reader (Molecular Devices) and Softmax Pro software. Binding was measured according to the assay manufacturer's instructions (Biacore). C1q, phosphatidylserine and calreticulin were immobilized on a CM5 sensor chip, and the binding affinity of SCARF1 was measured with Biacore 3000 system and software (GE Healthcare).
Nucleofection. A Nucleofector kit for Primary Mammalian Endothelial
Cells was used for the transfection of endothelial cells, and a Nucleofector kit V was used for the transfection of DCs and macrophages, according to the manufacturer's instructions (Lonza). Primary CD8α + DCs or macrophages (2 × 10 6 ) or endothelial cells (5 × 10 5 ) isolated from Scarf1 +/+ and Scarf1 −/− mice were transfected with a Nucleofector II by the Nucleofector program D-32 or M-002 with 2 µg mammalian expression vector encoding GFP alone (pMAX-GFP; Amaxa) or mouse SCARF1 tagged at the C terminus with GFP. Experiments were done 24 h later, at which time the transfection efficiency was >50% and cell viability was >80%, as determined by staining of GFP and with annexin V and propidium iodide, respectively. For flow cytometry, cells were pregated according to GFP expression for analysis of cells expressing GFP or SCARF1-GFP that captured red dye-labeled apoptotic cells.
Real-time quantitative PCR. Total RNA was extracted with an RNeasy kit and was treated with DNase according to the manufacturer's protocol (Qiagen), and each sample was reverse-transcribed with MultiScribe Reverse Transcriptase (Applied Biosystems). Each 25-µl volume for PCR contained 2 µl cDNA, 12.5 µl 2× SYBR Green Master Mix (Applied Biosystems) and 500 nM sense and antisense primers. Oligonucleotide primer sequences (designed on the PrimerBank website obtained from Integrated DNA Technologies) were as follows: human GAPDH, 5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-GAAGATGGTGATGGGATTTC-3′; human IL8, 5′-CTGGCCGTGGCTC TCTTG-3′ and 5′-CCTTGGCAAAACTGCACCTT-3′; mouse B2M, 5′-TT CTGGTGCTTGTCTCACTGA-3′ and 5′-CAGTATGTTCGGCTTCCCAT TC-3′; LOX-1, 5′-AAGCGAACCTTACTCAGCAGG-3′ and 5′-TGGATTTC TCATTCAGCTTCTGG; MARCO, 5′-CTGTGGCAATGGATCACTAGC-3′ and 5′-CTCCTGGCTGGTATGGACC-3′; SR-A1, 5′-TGAACGAGAGG ATGCTGACTG-3′ and 5′-GGAGGGGCCATTTTTAGTGC-3′; CD14, 5′-GC ACACTCACTCAACTTTTCCT-3′ and 5′-GCTGAGATCAGTCCTCTCT CG-3′; SCARF1, 5′-AGCCTGGAACTGCATGTCTT-3′ and 5′-TGAATGCC
